IP Library Granted Patent US 8,192,720
Granted Patent B2
US 8,192,720 · App. 12/701,149 · Granted Jun 5, 2012

Compositions and methods for detection, prevention, and treatment of anthrax and other infectious diseases

Assignee: Board of Regents of the Nevada System of Higher Education, on behalf of the University of Nevada, Reno
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,192,720
App. No.
12/701,149
Granted
Jun 5, 2012
Kind
B2
Abstract

Compositions and methods for the detection, prevention, or treatment of anthrax or other infectious diseases. In one aspect, the present invention provides methods for immunizing humans or animals against Bacillus anthracis or other capsulated pathogens. The methods include administering a capsular polypeptide of a pathogen of interest and a CD40 agonist to a human or animal. The capsular polypeptide or the CD40 agonist is administered in such an amount or frequency that an immunoprotective response can be elicited in the human or animal against the pathogen of interest. In another aspect, the present invention provides methods of using passive immunization with anti-capsular polypeptide antibodies to prevent or treat infections caused by Bacillus anthracis or other pathogens. In yet another aspect, the present invention provides methods useful for diagnosis of anthrax by detection of capsular polypeptide in serum or other biological samples.

Claims (9)

1. A method comprising administering poly γ- D -glutamic acid and a CD40 agonist to a vertebrate according to a regime such that an immune response is elicited in the vertebrate against Bacillus anthracis.

2. The method according to claim 1 , wherein the CD40 agonist is an agonistic anti-CD40 antibody.

3. The method according to claim 1 , wherein an administration of the CD40 agonist is simultaneous with, or separated by no more than 24 hours from, an administration of said poly γ- D -glutamic acid.

4. The method according to claim 1 , comprising at least one booster administration of said poly γ- D -glutamic acid after an initial administration of said poly γ- D -glutamic acid and the CD40 agonist.

5. The method according to claim 1 , wherein said vertebrate is a human.

6. The method according to claim 1 , wherein the poly γ- D -glutamic acid is isolated from Bacillus anthracis.

7. The method according to claim 1 , wherein the poly γ- D -glutamic acid is isolated from Bacillus lichenformis.

8. The method according to claim 1 , further comprising establishing an anti-γ D PGA antibody producing hybridoma from the vertebrate.

9. The method according to claim 8 , further comprising isolating anti-γ D PGA antibodies from the hybridoma.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jun 3, 2010
From: UNIVERSITY OF NEVADA RENO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024480/0210 →
Continuity (4)
Division 10809831 · Mar 26, 2004
Provisional Application 60502533 · Sep 12, 2003
Provisional Application 60529625 · Dec 16, 2003
Related Publication 20100291092A1 · Nov 18, 2010